 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045...

Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting

CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

Trevena Awarded OLINVYK Agreement with Premier, Inc.

Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12thCHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE...

Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries

Trevena, Inc. (NASDAQ:TRVN  Get Free Report)s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.87 and traded...

Trevena (NASDAQ:TRVN) Stock Passes Below 200-Day Moving Average of $0.87

Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable...

Trevena Reports Third Quarter 2023 Results and Provides Business Update

Research analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN  Get Free Report) in a research report issued on Tuesday. The firm set a sell rating on the...

Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

Trevena Q3 Earnings Preview

Company to host a Conference Call & Webcast at 8:00 a.m. ETCHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development...

Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia...

Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into...

Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Watchers	25,810
52-Wk Low	$0.5084
52-Wk High	$3.28

Market Cap	$9.49M
Volume (M)	167,655.00
52-Wk High	$3.28
52-Wk Low	$0.5084

TRVN Trevena Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community